Spelling suggestions: "subject:"epigenetics"" "subject:"epigeneticos""
771 |
Conception, synthèse et évaluation pharmacologique d’inhibiteurs potentiels de DOT1L impliqués dans la régulation épigénétique du cancer / Design, synthesis and pharmacological evaluation of potent DOT1L inhibitors involved in epigenetic regulation for cancer treatmentCastillo Aguilera, Omar 28 September 2017 (has links)
Le cancer, principale cause de mortalité dans le monde, est un problème majeur de santé publique. Malgré les nombreux traitements disponibles, il est nécessaire de développer de nouvelles thérapies plus efficaces et moins envahissantes. Aujourd’hui la connaissance du génome humain a dirigé la recherche vers de nouvelles approches: il est possible de moduler la réponse biologique en contrôlant l'accès aux informations génétiques via la régulation épigénétique.L’épigénétique est l’ensemble des modifications de l’expression des gènes n’entraînant pas de modifications dans la séquence d’ADN, qui mènent à un phénotype héritable et stable. Chez les eucaryotes, la régulation épigénétique implique des modifications covalentes de l'ADN (méthylation) et des histones (acétylation, méthylation…). Ces phénomènes modifient la structure de la chromatine, aboutissant à une configuration "ouverte" ou "fermée" permettant la transcription ou la répression de gènes. Dans une situation cancéreuse, le profil épigénétique est modifié ; la méthylation anormale de l’ADN ou des histones mène à la répression de certains gènes comme des gènes suppresseurs de tumeur, ou à l’expression des oncogènes. Contrairement aux changements génétiques irréversibles, les aberrations épigénétiques sont des modifications chimiques réversibles. Ainsi, des molécules capables de rétablir l'équilibre épigénétique représentent des outils thérapeutiques potentiels contre le cancer.La méthylation et l’acétylation sont les modifications épigénétiques les plus étudiées. La méthylation de l’ADN est catalysée par les ADN méthyltransférases (DNMTs), et la méthylation des histones par les histones méthyltransférases (HMTs).Le sujet de ce projet doctoral est porté sur les HMTs et en particulier sur DOT1L (DOT1 like, disruptor of telomericsilencing), responsable des méthylations du résidu Lys79 de l’histone 3 (H3K79), conduisant à la transcription des oncogènes. En effet, des études ont montré que DOT1L est liée à la leucémie et se révèle être une cible intéressante à inhiber. DOT1L comme les DNMT ont un même cofacteur : le SAM (S-adénosyl-L-méthionine). Certains de leurs inhibiteurs présentent un mécanisme d'inhibition commun : ils entrent en compétition avec SAM.Nous présentons la conception basée sur des études de modélisation moléculaire, et la synthèse multi-étapes des séries des molécules formées par 3 motifs principaux : a) un motif aminopyrimidine, b) un motif de type benzimidazole ou phénylurée, liés par c) un groupement phényle ou hétérocyclique. L’activité des composés synthétisés sur DOT1L a été évaluée et des relations structure-activité (RSA) ont été établies. L’activité sur DNMT et d’autres HMTs a été déterminée également afin d’étudier la spécificité de nos composés.Différents structures ont été identifiées comme point de départ pour aboutir à des inhibiteurs sélectives de DOT1L ou à des inhibiteurs mixtes DOT1L/DNMT. Ces molécules sont considérées comme des outils thérapeutiques intéressants dans le traitement du cancer. / Cancer is a serious issue of public health as it is one of the main causes of mortality worldwide. Despite the multiple available treatments, it is necessary to develop more efficient and less invasive therapies against cancer. The knowledge of the human genome and epigenome has directed research to new cancer treatment approaches: it is possible to modulate the biological outcome by controlling the access to the genetic information by means of the epigenetic regulation.Epigenetics are the changes happening on the genome without modifying its DNA sequence, leading to a heritable andstable phenotype. In the eukaryotic chromatin, epigenetic regulation implies covalent modifications of DNA and histones. These chemical modifications remodel the chromatin structure leading to an “opened” or “closed” configuration, which is related to the expression or repression of genes. The epigenetic landscape is altered in cancers; for example, abnormal methylation leads to the silencing of certain genes (such as tumor suppressor genes), or to the over-expression of oncogenes. Unlike genetic alterations that are irreversible, epigenetic aberrations are reversible. Thus, molecules that can reestablish the epigenetic balance represent potent therapeutic tools for cancer treatment.Methylation and acetylation are the most studied epigenetic modifications. DNA methylation is carried out by the DNAmethyltransferases (DNMTs) and histone methylation by the histone methyltransferases (HMTs).This PhD project was focused on the histone methyltransferase DOT1L (DOT1 like, disruptor of telomeric silencing), responsible of methylation of residue Lys79 of histone 3 (H3K79), which leads to the transcription of some oncogenes. Recent studies have shown that DOT1L is implicated in MLL-rearranged leukemia (MLL-r, Myeloid-Lymphoid Leukemia) thus it is a potent target in cancer. As DOT1L and DNMTs share the same cofactor, S-adenosyl-L-methionine (SAM), DNMT and DOT1L inhibitors can present a common inhibition mechanism by competing with SAM.We present herein the in silico – based design, and the multi-step synthesis of some series of molecules containing 3 main moieties: a) an aminopyrimidine motif and b) a benzimidazole or phenylurea motif, linked by c) a phenyl or heterocycle motif. DOT1L activity was determined for the different compounds synthesized and structure-activity relationships (SAR) were established. The activity on DNMT and other HMTs was determined as well, in other to study the DOT1L specificity of our compounds.Different scaffolds were identified to obtain DOT1L-selective or DOT1L/DNMT dual inhibitors. These molecules are interesting therapeutic tools for cancer treatment.
|
772 |
Using cell type-specific methods to understand molecular processes in the brainRajput, Ashish 01 June 2018 (has links)
No description available.
|
773 |
Efeito do tabagismo no perfil de metilação de DNA no promotor do gene SOCS-1 em células epiteliais da mucosa bucal de indivíduos portadores de periodontite crônica (fumantes e não fumantes) / Effect of smoking on the DNA methylation profile of the SOCS-1 gene promoter in oral mucosal epithelial cells of individuals with chronic periodontitis (smokers and nonsmokers)Martinez, Cristhiam de Jesus Hernandez 13 April 2018 (has links)
A periodontite está relacionada à genética do hospedeiro, constituição do biofilme dental e fatores ambientais como o hábito de fumar. A metilação do DNA é um mecanismo de expressão genética que pode inibir ou silenciar a expressão do gene. Desta forma, vários pesquisadores têm se dedicado a estudar a influência genética sobre a suscetibilidade e/ou risco aumentado à doença periodontal. Estudos têm relatado associação entre vários biomarcadores epigenéticos com a inflamação periodontal. Considerando a hipótese de que existe associação do tabagismo com a metilação em genes relacionados à doença periodontal, o objetivo deste estudo foi verificar o padrão de metilação do DNA em células do epitélio oral de pacientes com periodontite crônica (CP) no promotor de um gene específico envolvido no controle da inflamação, como supressor da sinalização de citocinas (SOCS-1) em pacientes fumantes e não fumantes. O gene SOCS-1 é localizado no cromossomo 16p13.3, compostos por uma região amino-terminal, um domínio SH2 central e uma caixa SOCS. É um regulador negativo da via JAK / STAT. Inibe os efeitos biológicos de várias citocinas, incluindo IL-2, IL-3, IL-4, IL-6, interferão (INF) - γ e INF- α / β. Este foi um estudo caso-controle, comparando dois grupos, um grupo (teste) com consumo de 10 cigarros mínimos por dia, com diagnóstico de periodontite crônica e outro grupo controle que foram pacientes não fumantes com periodontite crônica. Para tal, DNA genômico foi purificado de células epiteliais bucais obtidas por meio de enxágue com sacarose 3%, por tempo único de coleta. O DNA foi modificado pelo bissulfito de Sódio e os padrões de metilação do DNA foram analisados com a técnica MS-PCR (Polymerase chain reaction). A análise estatística foi realizada pela plataforma estatística R version 3.3.2 Core Team (2016). Foi realizado Teste t de Student para amostras independentes e teste não paramétrico de Wilcoxon & Mann-Whitney para variáveis qualitativas; teste qui-quadrado e para a variável metilação, foi feito um teste exato de Fisher para testar a associação entre os grupos e a metilação. Os resultados indicaram que, para células epiteliais da mucosa bucal, a frequência de desmetilação no gene SOCS-1 é maior no grupo sem o hábito do fumo, em comparação ao grupo fumante. Foram detectadas diferenças no padrão de metilação entre os dois grupos. Ao estabelecer uma estimativa de risco relativo entre os grupos e a variável metilação, foi observado que pacientes fumantes têm 7,08 vezes (risco relativo) com um intervalo (1,95-51.46) de apresentar doença periodontal crônica, com um padrão de metilação no gene SOCS-1 / Periodontitis is related to host genetics, constitution of the dental biofilm and environmental factors such as smoking. DNA methylation is a mechanism of genetic expression that can inhibit or silence gene expression. In this way several researchers have been dedicated to study the genetic influence on the susceptibility and / or increased risk to periodontal disease. Studies have reported association between several epigenetic biomarkers with periodontal inflammation. Considering the hypothesis that there is an association between smoking and methylation in genes related to periodontal disease, the objective of this study was to verify the DNA methylation pattern in oral epithelial cells of patients with chronic periodontitis (ChP) in the promoter of a specific gene involved in the control of inflammation, as suppressor of cytokine signaling (SOCS-1) in smokers and nonsmokers patients. The SOCS-1 gene is located on chromosome 16p13.3 composed of an amino-terminal region, a central SH2 domain and a SOCS box. It is a negative regulator of the JAK / STAT path. It inhibits the biological effects of various cytokines, including IL-2, IL-3, IL-4, IL-6, interferon (INF) -γ and INF-α / β . This was an case-control type study, comparing two groups, a group with consumption of 10 minimum cigarettes per day, with a diagnosis of chronic periodontitis and another control group were non-smokers with chronic periodontitis. For this, genomic DNA was purified from oral epithelial cells obtained by rinsing with 3% sucrose, for a single time of collection. The DNA was modified by Sodium bisulfite and the methylation patterns of the DNA were analyzed with the MS-PCR technique (Polymerase chain reaction). Statistical analysis was performed by the statistical platform R version 3.3.2 Core Team (2016), Student\'s t-test was performed for independent samples and Wilcoxon\'s & Mann-Whitney non-parametric test for qualitative variables; chi-square test. For the methylation variable, an exact Fisher\'s test was performed to test the association between the groups and the methylation. The results indicated that, for oral mucosal epithelial cells, the frequency of demethylation in the SOCS-1 gene is higher in the non-smoking group as compared to the smoker group. statistically significant differences were detected in the methylation pattern between the two groups. When establishing an relative risk between the groups and the methylation variable, it was observed that smokers are 7.08 times (relative risk) of having chronic periodontal disease with a methylation pattern in the SOCS-1 gene
|
774 |
Régulation de l'expression des oncogènes du papillomavirus humain de type 16 : étude dans des lignées cellulaires de cancers du col de l'utérus traitées avec un agent déméthylant / Oncogene expression regulation of human papillomavirus type 16 : study in cell lines of cervical cancers with a demethylating agentPerrard, Jérôme 20 May 2019 (has links)
Les papillomavirus humains (HPV) sont des petits virus non enveloppés à ADN double brin, qui infectent les épithéliums cutanés et muqueux. Très largement répandus dans la population humaine, les infections sont la plupart du temps asymptomatiques, tandis qu'une minorité provoquent des verrues cutanées, des condylomes acuminés et des carcinomes. Les cancers induits par HPV représentent 640 000 cas en 2012 dans le monde et sont localisés au niveau anogénital et au niveau des voies aérodigestives supérieures.La transformation des cellules est induite en particulier par la surexpression de deux oncoprotéines virales : E6 et E7, qui sont nécessaires à l'initiation, la promotion et la progression du phénotype cancéreux. Leur extinction provoque d'ailleurs la mort des cellules cancéreuses. E6 et E7 favorisent par exemple la dégradation de p53 et pRb, induisant ainsi une prolifération non contrôlée et accrue des cellules infectées. Mais les deux oncoprotéines virales interagissent aussi avec plus de 150 partenaires protéiques et dérégulent l'homéostasie cellulaire. Fait intéressant, E6 et E7 modulent l'expression de nombreuses protéines impliquées dans l'établissement des marques épigénétiques, impliquées dans la régulation de l'expression des gènes. D'ailleurs, la surexpression des oncoprotéines virales peut être liée à la méthylation de l'ADN d'une partie du génome viral.Puisque E6 et E7 détournent la machinerie épigénétique de la cellule, l'objectif du travail de thèse a été d'étudier les mécanismes moléculaires régulant l'expression des oncoprotéines lors du traitement des cellules de cancers du col par un agent déméthylant de l'ADN, le 5-aza-2'-déoxycytidine (5azadC).Dans des cellules issues de cancers du col de l'utérus, nous avons observé qu'un traitement déméthylant induisait une répression de la protéine E6 et une déstabilisation de ses transcrits, suggérant l'implication d'un miARN. Parmi les miARN ciblant les transcrits viraux, le miR-375 était le plus susceptible d'être impliqué dans la déstabilisation des transcrits car (i) la méthylation de son promoteur augmente avec la gravité des lésions du col de l'utérus, (ii) il cible les transcrits viraux au niveau de cinq régions différentes, et (iii) son expression est augmentée lors du traitement de cellules dérivées du cancer du col de l'utérus avec le 5azadC. Il s'est avéré que le miR-375 était effectivement impliqué dans la répression partielle des transcrits viraux lors du traitement. Les résultats de cette étude suggèrent par ailleurs qu'un autre mécanisme moléculaire pourrait être impliqué dans cette répression. C'est pourquoi, dans un deuxième temps, nous avons étudié l'implication possible d'un facteur de transcription, TBX2, dans la répression des transcrits viraux. Bien que le taux transcriptionnel de TBX2 soit augmenté lors du traitement des cellules avec des fortes concentrations de 5azadC, nos résultats suggèrent que la protéine n'est pas exprimée dans les cellules, même après traitement, et que TBX2 ne régule pas l'activité du promoteur viral intégré au génome cellulaire.Le traitement des cellules par l'agent déméthylant entraîne aussi une perte de viabilité en particulier des cellules Ca Ski. En effet, le 5azadC induit un blocage du cycle en G2/M dans ces cellules, une augmentation du pourcentage de cellules en Sub-G1 et un clivage de la PARP. Si le 5azadC est déjà utilisé en clinique pour le traitement d'autres cancers, nos données apportent un éclairage nouveau sur les mécanismes moléculaires du 5azadC dans les cancers induits par HPV, qui pourraient ainsi être traités par cette molécule. / Human papillomaviruses (HPV) are small, non-enveloped double-stranded DNA viruses and infect cutaneous and mucosal epithelia. Highly widespread in the human population, infections are mostly asymptomatic, while a minority causes cutaneous and genital warts, and carcinomas. HPV-induced cancers represent 640 000 cases in 2012 worldwide and are localized at the anogenital and head and neck sites.Cell transformation is induced by the overexpression of two viral oncoproteins E6 and E7, which are necessary for the initiation, promotion and progression of the cancerous phenotype. Indeed, their extinction causes cancer cell death. E6 and E7, for example, promote the degradation of p53 and pRb, thus inducing uncontrolled and increased proliferation of infected cells. But the two viral oncoproteins also interact with more than 150 protein partners and deregulate cell homeostasis. Interestingly, E6 and E7 modulate the expression of many proteins involved in the establishment of epigenetic marks, regulating gene expression. Furthermore, the overexpression of viral oncoproteins may be related to viral genome DNA methylation.Since E6 and E7 hijack epigenetic mechanisms, the aim of the thesis was to study the molecular mechanisms regulating the oncoprotein expression during the treatment of cervical cancer cells by a DNA demethylating agent, the 5-aza-2'-deoxycytidine (5azadC).In cervical cancer cells, we observed that a demethylating treatment induced E6 protein repression and destabilization of its transcripts, suggesting the involvement of a miRNA. Among miRNAs targeting viral transcripts, miR-375 was most likely to be involved this destabilization because (i) its promoter methylation increases with the severity of cervical lesions, (ii) it targets viral transcripts at five different regions, and (iii) its expression is increased in cervical cancer cells treated with 5azadC. In our experiences, miR-375 was indeed involved in the partial repression of viral transcripts during treatment. The results of this study further suggest that another molecular mechanism might be implicated in this repression. This is why, in a second step, we studied the possible involvement of a transcription factor, TBX2, in the viral transcript repression. Although the transcriptional rate of TBX2 is increased in cells treated with high concentrations of 5azadC, our results suggest that the protein is not expressed in cells, even after treatment, and that TBX2 does not regulate the viral promoter activity integrated into the cellular genome.Cell treatment with demethylating agent also leads to loss of viability, in particular in Ca Ski cells. Indeed, 5azadC induces a G2/M cycle arrest in these cells, an increase of Sub-G1 cells percentage and a PARP cleavage. While 5azadC is already used in clinical practice for the treatment of other cancers, our data shed new light on the molecular mechanisms of 5azadC in cancers induced by HPV, which could be treated by this molecule or analogues.
|
775 |
Alterações genéticas, epigenéticas e funcionais dos genes homeobox em carcinoma epidermoide de boca / Genetic, epigenetic and functional alterations of homeobox genes in oral squamous cell carcinomaDuarte, Carina Magalhães Esteves 02 October 2015 (has links)
Os genes homeobox atuam como reguladores da morfogênese e diferenciação celular embrionária, portanto, é evidente a possibilidade de sua expressão anormal estar presente na progressão de tumores. Estudos preliminares em nosso laboratório verificaram a participação de alguns genes homeobox em carcinoma epidermóide de boca (CEB). Este trabalho teve como objetivo avaliar a amplificação, expressão e o perfil de metilação dos genes HOXA5, HOXA7, HOXA9, HOXB5, HOXB13, HOXC12 em linhagem celular derivadas de CEB e tecidos frescos tumoral e não-tumoral. Além disso, verificar o efeito da desmetilação na expressão gênica de linhagens celulares que apresentaram genes 100% metilados e a participação das enzimas responsáveis pela metilação do DNA, bem como a expressão das DNAmetiltransferases (DNMT) nos tumores. A análise de amplificação do DNA e expressão de mRNA foi realizada por qRT-PCR. O perfil de metilação foi avaliada pelo sistema PCR Array e a análise proteica das DNMT1, DNMT3a, DNMT3b e HOXA9 foi verificada por meio de reações imunohistoquímicas. As linhagens celulares SCC4 e SCC9 foram utilizadas para análise de desmetilação com 5-aza-2\'-deoxicitidina e a linhagem SCC4 para avaliar os efeitos do aumento de expressão do HOXA9, na proliferação celular por imunocitoquimica para Ki67, migração celular por transwell e apoptose pela avaliação de células positivas no ensaio de TUNEL. Na comparação entre os grupos, o gene HOXA5 apresentou-se amplificado na margem em relação ao tumor; o HOXA9 apresentou nível de metilação aumentada no tumor; o HOXB5 com amplificação maior na margem, com nível de expressão do mRNA aumentada nos tumores, e nível de metilação do tumor maior em relação a margem, sendo correlacionada com menor sobrevida; HOXB13 se apresentou amplificado no tumor em relação a margem, e com nível de metilação maior nos tumores e, HOXC12 com níveis de metilação maior nos tumores em relação a margem. É interessante, que os mesmos genes que tiveram níveis de metilação aumentados nos tumores em relação a margem, também estavam 100% metilados nas linhagens celulares SCC4 e SCC9 e tiveram sua expressão restaurada após o tratamento com 5-aza-2´-deoxicitina. Na avaliação do nível de expressão das DNMTs nos tumores, a DNMT3b apresentou-se com níveis aumentados em relação a DNMT1 e DNMT3a, e quando avaliado em nível proteico, a DNMT3a pode ser correlacionada com melhor sobrevida. O aumento da expressão do gene HOXA9 mostrou diminuição da migração celular, porém não alterou a proliferação e apoptose celular. A expressão proteica não apresentou correlação com parâmetros clínicos. Em conclusão, os resultados mostram que os genes homeobox estudados estão pouco metilados nas linhagens celulares e em tecidos de CEB. A amplificação desses genes não é um evento frequente. O gene HOXA9 é pouco expresso no tumor, e o aumento da sua expressão em linhagens celulares diminui a migração celular. / Homeobox genes are important as morphogenetic and embrionary cellular differentiation regulators, therefore there is basis for their abnormal expression in tumor progression. Preliminary studies in our laboratory have shown that homeobox genes are dysregulated in oral squamous cell carcinoma (OSCC). This study evaluates the genomic amplification, mRNA expression and methylation status of HOXA5, HOXA7, HOXA9, HOXB5, HOXB13, HOXC12 in squamous cell carcinoma derived cell lines, and fresh tumor tissue. Also, analyzes the demethylation effect in gene expression of cell lines with genes showing 100% methylation, and the participation of enzymes responsible for DNA methylation, DNAmetiltransferases (DNMT), in gene and protein expression in tumors. DNA amplification and mRNA expression was analyzed by qRT-PCR. The methylation profile was evaluated by PCR Array System and DNMT1, DNMT3a, DNMT3b and HOXA9 protein expression was verified by immunohistochemistry. SCC4 and SCC9 cell lines were submitted to 5-aza-2\'-deoxycytidine for demethylation analysis. SCC4 cell lineage was analyzed by immunocytochemistry for Ki67, cell migration by transwell and apoptosis by TUNEL test after increased expression of HOXA9. HOXA5 gene was amplified in the adjacent margin when compared with the tumor; HOXA9 showed increased level of methylation in tumor; HOXB5 showed amplification in the margin, increased mRNA expression in tumors, increased methylation level and was correlated with decreased survival; HOXB13 was amplified in tumor samples when compared to the margins and also higher methylation level in tumors; and HOXC12 also showed increased methylation levels in tumors when compared to margin. Interestingly, the same genes with increased methylation levels in tumors, were also 100% methylated in cell lines SCC4 and SCC9. The expression of these gens was restored after treatment with 5-aza-2\'-deoxycytidine. DNMT3b presented higher levels of protein expression relative to DNMT1 and DNMT3a. DNMT3a protein expression was correlated with improved survival. SCC4 cells overexpressing HOXA9 gene showed decreased cell migration, with no effect on cell proliferation and apoptosis. HOXA9 protein expression was not correlated with clinical parameters. In conclusion, the results shows that homeobox genes are methylated in some OSCC cell lines and tissues. Amplification of these genes is not a frequent event. HOXA9 gene has low expression in OSCC, and when overexpressed in cell lines decreases cell migration.
|
776 |
Ácidos graxos de cadeia curta, produtos do metabolismo da microbiota intestinal, protegem da lesão renal aguda. / Short chain fatty acid, a metabolism product from gut microbiota, protect from acute kidney injury.Oliveira, Vinicius de Andrade 05 December 2014 (has links)
Os ácidos graxos de cadeia curta (AGCC) são produzidos pela microbiota intestinal e possuem papéis anti-inflamatórios e ação inibitória sobre histona deacetilases. A lesão renal aguda (LRA) é caracterizada por uma inflamação renal que influencia a função do rim. Este projeto avaliou se o tratamento com os AGCC impactaria nos desfechos inflamatórios da LRA em camundongos. Foi observado que o tratamento com AGCC, protege da LRA. Esta melhora foi associada a uma menor inflamação e menor taxa de apoptose. Além disso, o tratamento com acetato diminuiu a atividade de histona deacetilase. Administrando bactérias produtoras de acetato, também foi possível observar uma proteção da LRA, junto de uma menor inflamação sistêmica. Esta proteção do AGCC na LRA foi também observada em modelo de LRA secundária à sepse In vitro, o tratamento com AGCC modularam tanto células imunes como células renais sob estímulos inflamatórios e de hipóxia. AGCC modulam processos inflamatórios no rim via ações epigenéticas ou não, podendo ser uma promissora ferramenta na proteção da LRA. / Short-Chain Fatty Acids (SCFA) are produced by the intestinal microbiota and have anti-inflammatory and histone deacetylases inhibitors properties. Acute kidney injury (AKI) is characterized by renal inflammation that may impair kidney function. This project evaluated whether treatment with SCFA inflammatory impacts the outcomes of AKI in mice. It was observed that treatment with SCFA protected the AKI. This improvement was associated with less inflammation and lower apoptosis rate. In addition, treatment with acetate decreased the activity of histone deacetylase. Giving bacteria producing acetate, was also observed protection from AKI, along with a lower systemic inflammation. This protection of the AGCC in AKI was also observed in sepsis model. In vitro, SCFA treatment modulated both immune cells and renal cells under hypoxia and inflammatory stimuli. SCFA modulate inflammatory processes in the kidney via epigenetic actions or not, may be a promising tool in the protection of the AKI.
|
777 |
Análise da função dos microRNAs na regulação da expressão de DNMT3B/Dnmt3b e MECP2/Mecp2 / Analysis of microRNAs function in the regulation of DNMT3B/Dnmt3b and MECP2/Mecp2 gene expressionSchoof, Claudia Regina Gasque 30 January 2012 (has links)
A metilação do DNA em mamíferos é uma importante modificação epigenética, sendo essencial no silenciamento de DNAs repetitivos, de regiões que sofrem imprinting genômico e no estabelecimento do cromossomo X inativo em fêmeas. Existem 5 tipos de DNA Metiltransferases, tendo a DNMT3B um importante papel na metilação de novo. A MeCP2, por sua vez, é uma proteína capaz de reconhecer sítios de DNA metilados e recrutar proteínas responsáveis pela desacetilação das histonas. Isto provoca alterações na conformação da cromatina, impedindo a transcrição gênica. Alterações nos padrões de expressão de DNMT3B e na metilação do DNA encontradas em diferentes tipos de tumores, e a temporalidade de expressão de Dnmt3b e de Mecp2 durante ondas de desmetilação e de metilação que ocorrem no início do desenvolvimento embrionário, podem auxiliar na identificação de fatores envolvidos no estabelecimento e manutenção do padrão de metilação do DNA, os quais ainda são pouco conhecidos. Por sua vez, uma nova classe de pequenos RNAs, os microRNAs, envolvidos com a regulação da expressão gênica pós-transcricional, têm grande importância na manutenção do estado diferenciado de diferentes tipos celulares. Trabalhos recentes demonstram também que há alterações nos padrões de expressão de microRNAs entre tecidos normais e tumorais. Assim, é objetivo deste trabalho a identificação de possíveis miRNAs envolvidos na modulação da expressão dos genes DNMT3B/Dnmt3b e MeCP2/Mecp2 em diferentes linhagens de células normais e tumorais, bem como, em células tronco embrionárias humanas e murinas submetidas à diferenciação. / DNA methylation in mammals is an important epigenetic modification, playing an essential role in the silencing of repetitive DNA, in genomic imprinting and, in females, the establishment of X chromosome inactivation. There are 5 DNA metyhltransferases, and one of them, DNMT3B has an important role in de novo methylation. MeCP2, by its turn, is a protein capable of recognizing methylated DNA sites and of recruiting proteins responsible for histones deacetylation. This causes alterations in chromatin conformation, therefore inhibiting gene transcription. Changes in the expression patterns of DNMT3B and in DNA methylation are found in several types of tumors, and temporal expression of Dnmt3b and Mecp2 during global demetyhlation and de novo methylation waves, which occur in early embryonic development, could give a better understanding of the factors involved in the establishment and maintenance of DNA methylation patterns, which are still largely unkown. Additionally, a new class of small RNAs, the microRNAs, involved in the post-transcriptional gene silencing, has great importance in maintaining the differentiated state of several cell types. Recent studies have demonstrated alterations in miRNAs expression patterns between normal and tumor tissues. Thus, the aim of this work was to identify possible miRNAs involved in the modulation of Dnmt3b and Mecp2 RNAs in different normal and tumoral cell lines, as well as in human and murine embryonic stem cells and their respectively differentiated embryoid bodies.
|
778 |
Conséquences d'une carence en donneurs de méthyles sur le développement cérébral : implication du programme neurogénique et rôle de l'homocystéine / Consequences of a methyl donor deficiency on cerebral development : Implication of neurogenic program and role of homocysteineKerek, Racha 16 December 2013 (has links)
Les donneurs de méthyles (B12 et folates) régulent le cycle des monocarbones qui joue un rôle primordial dans les régulations épigénétiques/épigénomiques par méthylation. Une carence en donneurs de méthyles produit un retard de croissance intra-utérine et favorise les anomalies du développement, principalement du système nerveux central. De plus, des taux élevés d'homocystéine associés à une telle carence constituent un facteur de risque pour diverses pathologies neurodégénératives. Nous avons étudié les conséquences d'une carence péri-conceptionnelle et gestationnelle sur le développement cérébral embryonnaire de rats Wistar. L'étude morphométrique a montré un retard de croissance des embryons carencés qui affectait également le cerveau, avec une atrophie de structures telles que l'hippocampe, le cortex et la zone subventriculaire. En raison de la forte sensibilité de l'hippocampe, les effets de la carence ont par ailleurs été étudiés sur un modèle cellulaire de progéniteurs neuronaux hippocampiques. L'utilisation de ces deux modèles a permis de montrer in vivo et in vitro la régulation négative par la carence de la voie Stat3, qui influence prolifération et survie, via une régulation épigénomique post-transcriptionnelle impliquant miR-124. La dérégulation du programme neurogénique impliquant les histones désacétylases affecte la différenciation cellulaire. Par ailleurs, nous avons démontré que la carence en donneurs de méthyles était associée à une modification post-traductionnelle correspondant à une N-homocystéinylation irreversible de protéines neuronales, en particulier associées au cytosquelette. Cette modification induit l'agrégation des protéines, phénomène impliqué dans de nombreuses maladies neurodégénératives. La combinaison de ces différents mécanismes apporte un éclairage nouveau sur les défauts de développement et les troubles cognitifs associés à une carence précoce en donneurs de méthyles, soulignant l'importance de la « programmation foetale » dans la survenue de certaines pathologies neurologiques / Methyl donors (B12 and folate) regulate the one-carbon cycle that plays an important role in the epigenetic/epigenomic regulations by methylation. Methyl donor deficiency (MDD) leads to intrauterine growth retardation and promotes neurodevelopmental abnormalities. Also, high levels of homocysteine associated with such a deficiency are a risk factor for various neurodegenerative diseases. We have studied the consequences of a periconceptional and gestational deficiency on the development of the embryonic brain of Wistar rats. Morphometric studies showed retardation in the development of deficient embryos which also affected the brain, with an atrophy of some structures including hippocampus, cortex and subventricular zone. Given the high sensitivity of the hippocampus, the effects of MDD have been additionally studied in a cellular model of hippocampal neuronal progenitors. Using these two models, we showed both in vivo and in vitro the downregulation of Stat3 pathway regulating cell proliferation and survival, through an epigenomic post-transcriptional process involving miR-124. Disruption of the neurogenic program implying histone deacetylases was shown to alter cell differentiation. Furthermore, we showed that methyl donor deficiency was associated with a post-translational modification corresponding to an irreversible N- homocysteinylation of neuronal proteins, especially those associated with the cytoskeleton. Such a process leads to protein aggregation, a phenomenon involved in many neurodegenerative diseases. The combination of these different mechanisms provides new insights into developmental defects and cognitive impairment associated with an early MDD, highlighting the importance of "fetal programming" in the occurrence of some neurological diseases
|
779 |
Carence précoce en donneurs de méthyles dans le cervelet : mécanismes moléculaires et épigénétiques / Early methyl donor deficiency in cerebellum : molecular and epigenetic mechanismsWillekens, Jérèmy 18 December 2017 (has links)
Les carences précoces en donneurs de méthyles (vitamines B9 et B12 notamment) sont à l’origine de malformations congénitales. Elles exercent un effet délétère sur le développement du cerveau et sont associées à une augmentation de l’incidence de pathologies neurologiques et neurodégénératives à l’âge adulte. Un modèle murin de carence en donneurs de méthyles, le modèle MDD, a été développé au laboratoire et a permis d’étudier la réponse à cette carence, et de mettre en évidence des altérations de la structure cérébrale et des défauts de locomotion chez les ratons issus de mères carencées. Ce comportement est contrôlé par le cervelet, dont on sait que le développement est altéré chez les MDD. En revanche, les mécanismes moléculaires mis en jeu dans la réponse à la carence dans le cervelet restent peu compris. Afin d’étudier les gènes et voies de signalisation dérégulés chez les MDD, nous avons réalisé l’étude du transcriptome du cervelet des ratons carencés. Puis, nous nous sommes intéressés aux modifications épigénomiques engendrées par la carence en analysant leur miRnome et les modifications des protéines histones dans leur cervelet. Nous avons mis en évidence des altérations des voies wnt, dans le cervelet des femelles carencées, qui n’ont pas été retrouvées chez les mâles. De même, de nombreux gènes impliqués dans le développement et les fonctions synaptiques sont dérégulés chez les femelles. Nous avons aussi montré des variations de plusieurs marques d’acétylation et de méthylation des histones chez les MDD. Enfin, de manière plus ciblée, nous avons mis en évidence un miARN dont l’expression diminue dans le cervelet des ratons carencés : miR-344-5p. Nos premiers résultats semblent indiquer qu’il est impliqué dans le contrôle de la mort cellulaire. Ces résultats montrent l’implication de dérégulations globales dépendantes du sexe mais aussi des altérations ciblées dans la réponse à la carence. Une amélioration de la compréhension de ces mécanismes moléculaires nous permettra de mieux appréhender le lien qui existe entre carence précoce en donneurs de méthyles, développement cérébral et incidence de pathologies à l’âge adulte / Early methyl-donor deficiencies (e.g. B9 and B12 vitamins) can lead to congenital disabilities. They are behind developmental abnormalities of the brain, and are associated with the development of neurological and neurodegenerative diseases at adulthood as well. In the lab, we developed a methyl donor deficiency rat model called MDD. It has allowed us to show structure alterations of several brain areas and also locomotor coordination impairments in pups born from dams fed a MDD diet. Cerebellum is the brain structure involved in the control of this behavior and we know its development is delayed in MDD. However, the molecular mechanisms underlying methyl donor deficiency still remain misunderstood in this brain structure. In order to study genes and signaling pathways dysregulated in MDD, we performed transcriptomic analysis of deficient pups’ cerebellum. We also led miRnome analyses and histone modifications investigations with the purpose of understanding epigenomic modifications caused by MDD. We showed alterations of wnt signaling pathways in female’s cerebellum which we did not find in males. We also found that several genes involved in cerebellum’s development and synaptic function were dysregulated in females. Regarding epigenomic regulation, acetylation and methylation of histone marks were also modified in females. Finally, we chose miR-344-5p as an interesting candidate to study more specific epigenetic modifications. Its expression is decreased in MDD and it seems to be involved in cellular death control, according to our first results. These results shed light on global dysregulations, in a sex-dependent manner, as a consequence of methyl donor deficiency but also more specific alterations. A better understanding of the molecular mechanisms taking place in response to MDD could help us to link methyl donor deficiency, brain development and neurodegenerative pathologies occurrence at adulthood
|
780 |
Histone Deacetylase 1 and 2 are Essential for Early Cardiac DevelopmentMilstone, Zachary J. 03 April 2019 (has links)
Congenital heart disease is the most common congenital anomaly, affecting approximately 1% of all live births each year. Although clinical interventions are improving, many affected infants do not survive to adulthood. Congenital cardiac defects originate from disturbances during development, making the study of mammalian cardiogenesis critical to improving outcomes for infants with congenital heart disease. Development of the mammalian heart involves epigenetically-driven specification and commitment of a diverse landscape of cardiac progenitors. Recent studies determined that chromatin modifying enzymes play a previously underappreciated role in the pathogenesis of congenital heart defects. This thesis investigates the functions of Hdac1 and Hdac2, highly homologous Class I histone deacetylases, during early murine cardiac development. We establish that Hdac1 and Hdac2 cooperatively regulate cardiogenesis in distinct cardiac progenitor populations during development. Together, our findings demonstrate that Hdac1 and Hdac2 are critical mediators of the earliest stages of mammalian cardiogenesis through a variety of spatiotemporally specific, redundant, and dose-sensitive roles and indicate they may play important roles in the pathogenesis of human congenital cardiac defects.
|
Page generated in 0.0576 seconds